HOME >> BIOLOGY >> NEWS
ChemGenex reports successful personalized dosing of Quinamed at ASCO

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 4, 2007). ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the presentation of data from its Quinamed (amonafide dihydrochloride) phase 1/2a dose-escalation study, designed to identify a genotypically optimised dose of Quinamed in heavily pre-treated patients with a variety of solid tumors. The key outcomes from this study were (i) demonstration that dose level could be optimised according to patient genotype, (ii) the drug was well tolerated, with predictable and manageable side effects, and (iii) there was evidence of anticancer activity in several solid tumor types.

Dr. John Kuhn of the University of Texas Health Science Center in San Antonio, TX, along with the investigators at Sarah Cannon Cancer Center, TN and University of Louisville, KY discussed the data in an oral presentation at the American Association of Clinical Oncology (ASCO) 43rd Annual Meeting in Chicago, Illinois.

The clinical activity of amonafide against a variety of cancers has long been recognized, but development has been hampered by the unpredictable side effect profile for patients said Dr Kuhn. We are excited by the new opportunities that personalized dosing of Quinamed offers for a range of solid tumor patients who have developed resistance to existing therapies.

Highlights of the presentation included:

  • Confirmation that genotyping of patients prior to treatment allows for optimized personalized dosing and improved drug tolerance.
  • Patients with rapid and intermediate acetylator genotypes (who more rapidly metabolize the drug to the acetylated derivative associated with side effects) achieved a maximum tolerated dose (MTD) of 320 mg/m2 of Quinamed weekly, whilst patients with slow acetylator genotypes achieved an MTD of 400 mg/m2 of Quinamed weekly (three weeks on treatment followed by one week off treatment, repeated). Using these dosing regimens, 64% of
    '"/>


Contact: Joan Kureczka
jkureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
4-Jun-2007


Page: 1 2

Related biology news :

1. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML
2. 1 month post launch, Interactive Autism Network reports 13,000 participants
3. Biosite reports on presentation of preliminary data from sepsis program
4. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
5. Orexigen reports positive phase II results for Excalia Combination-Therapy to treat obesity
6. Dinosaurs climate shifted too, reports show
7. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
8. Portion distortion may contribute to expanding waistlines, study reports
9. Study reports findings on lung cancer death rates in never smokers
10. Breast implants not associated with cancer risk, study reports
11. Paper reports discovery of virus implicated in genetics of prostate cancer

Post Your Comments:
(Date:5/24/2013)... world,s largest and fastest growing open-access publishers, today announces ... Physics . , A broad scope journal covering all ... open-science and interactive web platform for the research community ... , Frontiers, real-time and interactive peer-review enables fast, fair ... With an average of three months from submission to ...
(Date:5/24/2013)... years, microRNAs (miRNAs) and other non-coding RNAs are ... specific proteins. In recent years they have emerged ... to establish tissue origin for cancers of unknown ... screen for disease, but clinically tractable, diagnostic methods ... not currently available. In this issue of the ...
(Date:5/24/2013)... leading water scientists from around the world today issued ... short span of one or two generations, the majority ... living under the handicap of severe pressure on fresh ... is no substitute. This handicap will be self-inflicted and ... pointed to chronic underlying problems led by mismanagement and ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4
(Date:5/24/2013)... New York, NY (PRWEB) May 24, 2013 ... help the public protect themselves from the looming higher risk ... Cleaning Products published a new bed bug guideline. In the ... of bed bugs and avoiding them while traveling. ... why there is an increase of bed bug infestation during ...
(Date:5/24/2013)... 2013 Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients, ... Ph.D., the Company,s Vice President, Biology and ... Corporate Communications, will present an overview of Senomyx,s technology ... Eastern Time (7:25 a.m. Pacific Time) during the Citi ...
(Date:5/24/2013)... Toronto, Canada (PRWEB) May 24, 2013 ... selective barriers, and uptake or efflux transporters at the ... may be related to unbound fractions in the tissue ... understanding of these disposition challenges is required to guide ... and to identify any species-dependent variables that may impact ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Vestiage, ... lifestyle company focused on science-based research and development, ... anti-aging cosmeceuticals and nutraceuticals, announced today that it ... States for the sale of Reluma Skin Illuminating ... packet and application by sending an email to ...
Breaking Biology Technology:Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5
Cached News: